Ionis Pharmaceuticals stock
IONSNASDAQIonis Pharmaceuticals, Inc., HealthcareISIN US4622221004
32Score 32 out of 100, Weak
Price and trend
24 / 100
Price history
−62% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 58% below it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 13).
The price is 68% below its 52-week high. Largest decline in 20 years: 73% (March 2015 to June 2016).
Chart figures for advanced users
- SMA 50$44.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$64.77
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)13
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$27.31
- The lowest closing price of the last twelve months.
- Resistance$86.50
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ionis Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $4.55B, is number 78 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $944M (up 33.9% year on year) and a loss of $381M.
- For fiscal 2026, analysts expect on average revenue of $924.97M (down 2%) and adjusted earnings per share of −$3.58.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 659 of 702 in Healthcare, median 53.
- Our model puts fair value at $61.55, with the price 56% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $2.68B, financial debt $2.61B (fiscal 2025).
Weaknesses
- High debtDebt 5.35 times equity (fiscal 2025), Biotechnology median 0.09.Stability 31
- Loss-makingLoss of $546.15M over the last 12 months.Fundamentals 17
- Share price fell sharplyDown 62% over the last 12 months.Momentum 12
Its standout strength is valuation, while fundamentals and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $43.97 and expensive above $102.59 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 11.4%. At 12.4% the fair value would be $51.74, at 10.4% it would be $74.53.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 0.7% on the twelve months before. Revenue has grown strongly since 2006, at around 24% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating −40%, net −40%. Last 12 months: net −57%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 9 Nov 2026EPS reported −$0.66 (expected −$1.23)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.58+0.7%
- Revenue
- $924.97M+0.3%
- Earnings per share
- −$2.08+0.8%
- Revenue
- $1.34B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.7%2026 financial guidance reaffirmed, operating expenses expected to rise in the low teens percent, goal of cash flow breakeven in 2028.
“We remain on track to deliver on our 2026 financial guidance and achieve our goal of cash flow breakeven in 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $1.06M in total. 11 insiders sold, $19.99M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Devers Shannon L.Sale
16 Oct 2026, EVP, Chief Human Resources Ofc
- Shares
- 1,357
- Price
- $43.54
- Value
- $59,082
- Swayze EricSale
16 Oct 2026, EVP Research
- Shares
- 53
- Price
- $43.54
- Value
- $2,308
- Hayden Michael RPurchase
31 Jul 2026, Board
- Shares
- 5,000
- Price
- $51.60
- Value
- $258,000
Show 16 more
- Hayden Michael RPurchase
30 Jul 2026, Board
- Shares
- 15,000
- Price
- $53.38
- Value
- $800,700
- Bennett C FrankSale
7 Jul 2026, EVP, Chief Scientific Officer
- Shares
- 20,536
- Price
- $84.95
- Value
- $1.74M
- Diaz Allene M.Sale
7 Jul 2026, Board
- Shares
- 10,111
- Price
- $85.42
- Value
- $863,637
- Kordasiewicz Holly B.Sale
7 Jul 2026, EVP, Chief Development Officer
- Shares
- 362
- Price
- $84.30
- Value
- $30,517
- Klein Joseph IiiSale
1 Jul 2026, Board
- Shares
- 11,518
- Price
- $79.04
- Value
- $910,416
- Baroldi JosephSale
26 Jun 2026, EVP, Chief Business Officer
- Shares
- 5,635
- Price
- $80.16
- Value
- $451,699
- O'Neil Patrick R.Sale
26 Jun 2026, EVP CLO & General Counsel
- Shares
- 3,069
- Price
- $80.00
- Value
- $245,520
- Schneider EugeneSale
26 Jun 2026, EVP, Chf Clinical Develop Ofcr
- Shares
- 26,000
- Price
- $81.05
- Value
- $2.11M
- Monia Brett PSale
26 Jun 2026, Chief Executive Officer
- Shares
- 50,000
- Price
- $80.59
- Value
- $4.03M
- Monia Brett PSale
25 Jun 2026, Chief Executive Officer
- Shares
- 21,072
- Price
- $78.49
- Value
- $1.65M
- Swayze EricSale
25 Jun 2026, EVP Research
- Shares
- 10,602
- Price
- $79.18
- Value
- $839,492
- Monia Brett PSale
24 Jun 2026, Chief Executive Officer
- Shares
- 14,565
- Price
- $78.41
- Value
- $1.14M
- Berthelsen Spencer RSale
15 Jun 2026, Board
- Shares
- 8,000
- Price
- $73.49
- Value
- $587,920
- Kordasiewicz Holly B.Sale
12 Jun 2026, EVP, Chief Development Officer
- Shares
- 60,846
- Price
- $73.41
- Value
- $4.47M
- Berthelsen Spencer RSale
1 Jun 2026, Board
- Shares
- 8,000
- Price
- $75.67
- Value
- $605,360
- Monia Brett PSale
14 May 2026, Chief Executive Officer
- Shares
- 3,220
- Price
- $78.68
- Value
- $253,347
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ionis Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Cogent BiosciencesCOGT $5.07B28
- Travere TherapeuticsTVTX $4.95B50
- Edgewise TherapeuticsEWTX $4.93B54
- Adaptive BiotechnologiesADPT $4.77B47
- Definium TherapeuticsDFTX $4.52B41
- CamurusCAMX.ST $4.41B74
- Tango TherapeuticsTNGX $4.21B46
- CRISPR TherapeuticsCRSP $4.13B34
ETFs that hold Ionis Pharmaceuticals
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 1.72% | 0.49% | €26.29M |
| Harbor Health Care UCITS ETF AccW311 | 1.18% | 0.89% | €11.72M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.42% | 0.35% | €1.25B |
Show 5 more
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.24% | 0.25% | €45.16M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.12% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.06% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.10% | €395.74M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.03% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2021)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.